Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome

In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated: reducing the number of drugs from dual to single antiplatelet therapy, and lowering the dose of prasugrel from 10 mg to 5 mg. They conclude by highlighting the key results and what they may mean for clinical decision-making.

Watch this interview to get clear, practical insights into a trial that could shape how we approach antithrombotic therapy in ACS moving forward.

This interview was filmed at EuroPCR 2025: see more videos here.